Navigation Links
Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
Date:10/1/2008

VEDBAEK, Denmark, October 1 /PRNewswire-FirstCall/ --

- Announcement No. 40/2008

- To OMX Nordic Exchange Copenhagen and the Press.

Exiqon A/S today announces a grant of license to Roche Diagnostics for use of the Universal ProbeLibrary that is based on Exiqon's proprietary LNA(TM) detection technology.

Roche Diagnostics will develop its new product line for RealTime ready qPCR assays with the Universal ProbeLibrary that is based on Exiqon's proprietary LNA(TM) detection technology.

"This extension of our successful partnership with Roche allows for the application of Exiqon's LNA(TM) detection technology in the new and fast growing market for ready-to-use and customizable RealTime PCR products. We are exited to have Roche Diagnostics, who is a leader in the RealTime PCR market, embrace the LNA(TM) detection technology in their new product offering," comments Lars Kongsbak, President and CEO of Exiqon."

For additional information, reference is made to the attached press release by the parties.

The financial details of the agreement including commercial milestone payments and royalties on future product sales are not disclosed.

Exiqon retains its financial outlook for 2008 including an expected revenue of DKK 140-150 million in 2008 including both research product sales and 10 months of diagnostic sales from Oncotech's activities corresponding to full year revenues including Oncotech of DKK 150-160 million and a net loss for the year 2008 of DKK 100-115 including DKK 6 million of costs of current incentive plans, including warrants..

Exiqon maintains its long-term financial goal of profitability by 2011 with its current cash position and break even of the research products business by 2009.

About Exiqon

Exiqon is dedicated to personalizing the treatment selection for cancer patients. Our goal is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
2. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
5. Exiqon: Major Shareholder Announcement
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
11. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... PHILADELPHIA and LONDON, June 9 /PRNewswire/ -- ... today that, despite difficult economic times, renewals of ... existing customers have even added new content to their ... the world,s largest citation database, providing researchers, administrators, faculty ...
... Personalized Medicine Company in Next Phase of Growth , , ... personalized medicine company, announced today that James S. ... CEO. , , Burns comes to AssureRx with more ... science and technology for pharmaceutical, diagnostic, and biotech companies. Most recently, ...
... MARINO, Calif., June 9 Epeius Biotechnologies, Rexin-G is the ... you will, a tiny particle that can travel freely within ... that have spread far and wide. Imagine an entire ... high concentrations within the flagrant, otherwise intractable tumors with one ...
Cached Biology Technology:Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate 2AssureRx Adds New CEO 2The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers 2
(Date:8/29/2014)... is available in German . ... between organisms is considered the oldest form of communication. ... conspecifics, for example, the sexual attraction between males and ... and to coordinate reproductive behavior in males and females. ... of the Algarve in Faro, Portugal, and at the ...
(Date:8/29/2014)... Tibetan plateau -- the largest topographic anomaly above sea ... profound effect on climate and its reflection of continental ... , Katharine Huntington and colleagues employ a cutting-edge geochemical ... fossil snail shells to investigate the uplift history of ... range widely on the timing of surface uplift of ...
(Date:8/28/2014)... study reports that an expansion of marine protected areas ... ecological functions. According to investigators from the Wildlife ... fish have focused on saving the largest numbers of ... provide key and difficult-to-replace ecological functions. , ... by fish species that also are food for millions ...
Breaking Biology News(10 mins):Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... vaccine has successfully protected mice and ferrets against a ... who led the study at St. Jude Children's Research ... San Diego, California. , This finding, coupled with results ... influenza strains, suggests that such a vaccine would protect ...
... the bacteria which survive in extreme cold, scientists no ... Antarctic lakes and glaciers. Bacteria previously isolated from polar ... in extreme cold, have been isolated from soil in ... at Queen's University, Canada, have developed a technique to ...
... combining the four bacterial surface proteins that generate ... the University of Chicago have created a vaccine ... drug-resistant strains of Staphylococcus aureus, the most common ... source of community-associated illness. , The vaccine ...
Cached Biology News:St. Jude test of bird flu vaccine proves successful 2MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3
... a member of the caudal-related homeobox family, ... both proliferation and differentiation in intestinal epithelial ... triggering cells towards the phenotype of differentiated ... maintenance of the phenotype. Clone CDX2-88 reacts ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
Biology Products: